Potential benefits resulting from the ischemic biomarkers’ assessment in the later phase of stroke can be related with information about its progression (biomarkers: GFAP, S100β, IL-6, MMP-9), monitoring of the results of therapy (IL-6, S100β, MMP-9), and estimation of the outcome prognosis (IL-6, S100β, vWF; BDNF) [3, 217, 221]. The gene discussed is VWF; the disease is Stroke.